Advertisement
In the healthcare sector Hims & Hers Health Inc stock closed at 49.28 USD, recording a sharp decline of 10.98 USD (-18.22%) over the past five days. This significant drop came after the US FDA announced that Ozempic, Wegovy shortages have come to an end. However, in the initial half of the week, the healthcare stock surged after the company revealed that it has acquired at-home lab testing provider Sigmund, or Trybe Labs, to allow the company to offer at-home blood testing
On February 21 at 7:59 PM GMT-5, the stock saw a wide trading range, reaching a high of 57.37 USD and a low of 49.05 USD during the session. The stock opened at 53.51 USD. In after-hours trading, the stock slipped further by 0.28 USD (0.57%), bringing its price to 49.00 USD, indicating continued caution among investors.
With a market capitalization of 1.08KCr, Hims & Hers Health continues to retain its position in the healthcare sector.
Disclaimer: This article is for informational purposes only and does not constitute any financial advice.